Prognostic Significance of Mutation Type and Chromosome Fragility in Fanconi Anemia
1 other identifier
observational
227
1 country
1
Brief Summary
The goal of this observational study is to analyze the data included in the Spanish Registry of Patients with Fanconi anemia to better understand the natural history of the disease, identify genetic risk and prognostic factors, and identify potential therapeutic strategies.
Trial Health
Trial Health Score
Automated assessment based on enrollment pace, timeline, and geographic reach
participants targeted
Target at P75+ for all trials
Started May 2024
Shorter than P25 for all trials
1 active site
Health score is calculated from publicly available data and should be used for screening purposes only.
Trial Relationships
Click on a node to explore related trials.
Study Timeline
Key milestones and dates
Study Start
First participant enrolled
May 16, 2024
CompletedFirst Submitted
Initial submission to the registry
May 17, 2024
CompletedPrimary Completion
Last participant's last visit for primary outcome
June 18, 2024
CompletedStudy Completion
Last participant's last visit for all outcomes
June 18, 2024
CompletedFirst Posted
Study publicly available on registry
July 8, 2024
CompletedJuly 8, 2024
June 1, 2024
1 month
May 17, 2024
June 28, 2024
Conditions
Outcome Measures
Primary Outcomes (1)
Description of the clinical evolution of the patient
Study the clinical evolution of patients with Fanconi anemia
1 month
Eligibility Criteria
Patients with Fanconi anemia included in the Spanish Registry
You may qualify if:
- All patients in the Spanish Registry of Patients with Fanconi Anemia
Contact the study team to confirm eligibility.
Sponsors & Collaborators
Study Sites (1)
Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau - IIB Sant Pau
Barcelona, 08041, Spain
Related Publications (1)
Ramirez MJ, Pujol R, Minguillon J, Bogliolo M, Persico I, Cavero D, de la Cal A, Rio P, Navarro S, Casado JA, Bailador A, de la Fuente AS, de Heredia ML, Almazan F, Antelo ML, Argiles B, Badell I, Baragano M, Belendez C, Bermudez M, Bernues M, Buedo MI, Carrasco E, Catala A, Costa D, Cuesta I, Fernandez-Delgado R, Fernandez-Teijeiro A, Figuera A, Garcia M, Gondra A, Gonzalez M, Muniz SG, Hernandez-Rodriguez I, Ibanez F, Kelleher NJ, Lendinez F, Lopez M, Lopez-Almaraz R, Marchante I, Mendoza C, Nieto J, Ojeda E, Payan-Pernia S, Pelaez I, de Soto IP, Portugal R, Ramos-Arroyo MA, Regueiro A, Rodriguez A, Rosell J, Saez R, Sanchez J, Sanchez M, Senent M, Tapia M, Trujillo-Quintero JP, Vagace JM, Verdu-Amoros J, Verdugo V, Vidales I, Villarreal J, Diaz-de-Heredia C, Sevilla J, Bueren JA, Surralles J. Prognostic significance of mutation type and chromosome fragility in Fanconi anemia. Am J Hematol. 2025 Feb;100(2):272-284. doi: 10.1002/ajh.27520. Epub 2024 Nov 19.
PMID: 39562502DERIVED
MeSH Terms
Conditions
Condition Hierarchy (Ancestors)
Study Officials
- PRINCIPAL INVESTIGATOR
Jordi Surrallés, PhD
Institut de Recerca Sant Pau (IR SANT PAU), Barcelona, Spain
Study Design
- Study Type
- observational
- Observational Model
- COHORT
- Time Perspective
- OTHER
- Sponsor Type
- OTHER
- Responsible Party
- SPONSOR
Study Record Dates
First Submitted
May 17, 2024
First Posted
July 8, 2024
Study Start
May 16, 2024
Primary Completion
June 18, 2024
Study Completion
June 18, 2024
Last Updated
July 8, 2024
Record last verified: 2024-06